Venous Thromboembolism in Medical Inpatients: Prophylaxis With Low-Weight Heparin in a University Hospital and Prevalence of Thromboembolic Events

Abstract

The aim of this study was to determine the prevalence of venous thromboembolism (VT) in current prophylactic practice with low-molecular-weight heparin (LMWH) among medical inpatients and to analyze associated risk factors for VT.

A cross-sectional survey on five given days was conducted in the medical departments of a university hospital. The prevalence of prophylaxis and confirmed VT was measured. Risk markers for receiving high doses of LMWH and for VT under prophylaxis were assessed by logistic regression models.

Of 1194 inpatients, 1.4% suffered VT. The mean proportion of patients with LMWH prophylaxis was 24% (range: 4-64°k). The prevalence of VT was higher among inpatients receiving prophylaxis than among those patients not receiving prophylaxis (3.5% vs. 0.7%, p = 0.002). Under prophylaxis, independent risk markers for thrombosis were history of vein thrombosis (odds ratio [OR]: 4.03; confidence interval [95%CI]: 1.04-15.62) and age (OR: 1.08 ; 95%CI: 1.01-1.15). Two factors were independently associated with the prescription of high doses of LMWH: obesity was positively associated (OR: 7.50; 95%CI: 2.97-18.92; p < 0.0001) and respiratory insufficiency was negatively associated.

In medical departments, current prophylaxis practice leads to many patients being given LMWH. LMWH doses and other preventive measures should be adapted in high-risk inpatients.

References

THRIFR consensus group. Risk and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992.305:567.

Gross JS , Neufeld RR Libow LS , et al. Autopsy study of the elderly institutionalized patients. Review of 234 autopsies. Arch Intern Med 1988,148:173.

Lindblad B. , Sternby NH , Berqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years . BMJ 1991,302: 709.

Kierkegaard A. , Norgren L. , Olsson CG , et al. incidence of deep vein thrombosis in bedridden non-surgical patients. Acta Med Scand 1987:222:409.

Prescott RJ , Jones DR , Vasilescu C. , et al. Smoking and risk factors in deep vein thrombosis. Thromb Haemost 1978;40:128.

Belch JJ , Lowe GD , Ward AG , et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115.

Duhan R. Houlbert D , Caulin C. , et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomised double-blind trial. Haemostasis 1986;16:159.

Lechler E. , Schramm W. , Flosbach CW The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996:26(suppl 2):49.

Samama MM , Cohen AT , Darmon JY , et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793.

10.

Bouthier J. The venous thrombotic risk in nonsurgical patients . Drugs 1996;52(suppl 7):16.

11.

Anderson FA , Wheeler HB , Goldberg RJ , et al. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992:152:1660.

12.

Coon WW , Willis PW , Keller JB Venous thrombo-embolism and other venous disease in the Tecumseh community health study. Circulation 1973;48:839.

13.

Hirsh J. Hull RD , Raskob GE Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol 1986;8:104B.

14.

Janssen HF Schachner J. , Hubbard J. , et al. The risk of deep vein thrombosis: a computerized epidemiotosic approach. Surgery 1987;101:205.

15.

Salzman EW , Hirsh J. Prevention of venous thromboembolism. In: Colman RW , Hirsh J , Marder V , et al., eds. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Company, 1987:1252.

16.

Cade JF High risk of the critically ill for venous thromboembolism. Crit Care Med 1982,10:448.

17.

Harenberg J. , Roebruck P. , Heene DL , et al. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996; 26:127,

18.

Bergmann JF , Neuhart E. A multicenter randomised double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembotic disease in elderly inpatients bedridden for acute medical illness . Thromb Haemost 1996;76:529.

19.

Harenberg J. , Kaltenbach B. , Martin U. et al. Randomised controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990;59: 639.

20.

Sandler DA , Martin JF , Duncan JS , et al. Diagnosis of deep vein thrombosis: comparison of clinical evaluation, ultrasound, plethysmography, and venoscan with X-ray venogram. Lancet 1984; 2:716.

21.

Wells PS , Hirsh J. Anderson DR , et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995;345:1326.

22.

Anderson DR , Lensing Awa , Wells PS , et al. Limitations of impedance piethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med 1993; 118:25.